175 related articles for article (PubMed ID: 30346848)
1. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
[TBL] [Abstract][Full Text] [Related]
2. Inhaled salbutamol from aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients.
Boshra MS; Almeldien AG; Eldin RS; Elberry AA; Abdelwahab NS; Salem MN; Rabea H; Abdelrahim MEA
Exp Lung Res; 2019; 45(3-4):84-91. PubMed ID: 31155973
[TBL] [Abstract][Full Text] [Related]
3. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
Broeders ME; Molema J; Burnell PK; Folgering HT
J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
[TBL] [Abstract][Full Text] [Related]
4. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
Broeders ME; Molema J; Hop WC; Folgering HT
J Aerosol Med; 2003; 16(2):131-41. PubMed ID: 12823907
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees.
Ali AMA; Zawbaa HM; Sayed OM; Harb HS; Saeed H; Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Salem MN; Rabea H; Wael W; Hussein RRS; Sarhan RM; Ramadan W; Madney YM; Abdelrahim MEA
Int J Clin Pract; 2021 Mar; 75(3):e13764. PubMed ID: 33067907
[TBL] [Abstract][Full Text] [Related]
6. Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions.
Abdelrahim ME
Respir Med; 2010 May; 104(5):682-9. PubMed ID: 20004090
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
8. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
9. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Comparison of Two Blister-Type Inhalers.
Kondo T; Tanigaki T; Hibino M; Tajiri S; Horiuchi S; Maeda K; Tobe S
Respir Care; 2023 Mar; 68(3):338-345. PubMed ID: 36100278
[TBL] [Abstract][Full Text] [Related]
11. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
Chew NY; Chan HK
J Aerosol Med; 2001; 14(4):495-501. PubMed ID: 11791690
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
13. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume.
Yakubu SI; Assi KH; Chrystyn H
Int J Pharm; 2013 Oct; 455(1-2):213-8. PubMed ID: 23892154
[TBL] [Abstract][Full Text] [Related]
14. Patient Inspiratory Maneuver Performance; Peak Lungpower, Acceleration and Volume.
Haikarainen J; Vahteristo M; Lähelmä S; Vartiainen V; Malmberg LP
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):305-313. PubMed ID: 32423277
[No Abstract] [Full Text] [Related]
15. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
16. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
17. Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.
Broeders ME; Molema J; Hop WC; Folgering HT
Eur J Clin Pharmacol; 2005 Feb; 60(12):837-41. PubMed ID: 15625613
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
[TBL] [Abstract][Full Text] [Related]
19. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
Molimard M; Till D; Stenglein S; Singh D; Krummen M
Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
[TBL] [Abstract][Full Text] [Related]
20. Exhalation immediately before inhalation optimizes dry powder inhaler use.
Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
